Teva to Cut 7,000 Jobs After Disappointing Quarter Results
Teva Pharmaceuticals - Wikipedia
Teva Pharmaceutical Industries Ltd. Slashes Full-Year Outlook After Disappointing Second Quarter | The Motley Fool
Teva and OncoGenex announce top-line survival results of Phase III SYNERGY trial evaluating custirsen in combination with first-line docetaxel and prednisone - Drug Target Review
Teva Pharmaceutical loses another CEO, leaving investors to guess what's next | Mint
Teva Pharmaceuticals: Making Quality Health Care Accessible
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel